ASTX727, Venetoclax, and Gilteritinib
A Phase I/II Study of ASTX727, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 42 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- BCL-2 Inhibitor, Cytidine Deaminase Inhibitor (CDAi), Nucleoside Metabolic Inhibitor, Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1507
- NCT Identifier
- NCT05010122
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.